Charles Zou
Impact in
-
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
-
- Protein Degradation and Inhibitors
- Ubiquitin and proteasome pathways
- Protein Tyrosine Phosphatases
- Histone Deacetylase Inhibitors Research
Papers in
- Oncology 5
- CAR-T cell therapy research 2
-
- Multiple Myeloma Research and Treatments 2
- Acute Myeloid Leukemia Research 1
- Co-authors
- Mikolaj Michal Slabicki (6 shared papers)Eric S. Fischer (3 shared papers)Benjamin L. Ebert (4 shared papers)Katherine A. Donovan (2 shared papers)Marko Cigler (1 shared paper)Georg Petzold (2 shared papers)Dakota J. Suchyta (1 shared paper)Georg Kempf (1 shared paper)
- Journals
- Nature Chemical Biology (2 papers)Nature (2 papers)Molecular Cell (2 papers)ACS Chemical Biology (1 paper)Science (1 paper)
- Partner nations
- United StatesSwitzerlandGermany
In The Last Decade
Charles Zou
14 papers receiving 778 citations
Peers
Comparison fields: 5 of 65
- Oncology 229
- Molecular Biology 588
- Cancer Research 74
- Hematology 50
- Immunology 78
Countries citing papers authored by Charles Zou
This map shows the geographic impact of Charles Zou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles Zou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles Zou more than expected).
Fields of papers citing papers by Charles Zou
This network shows the impact of papers produced by Charles Zou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles Zou. The network helps show where Charles Zou may publish in the future.
Co-authors
The 25 scholars most cited alongside Charles Zou, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 214 | |
| 2 | 2020 | 213 | |
| 3 | 2023 | 86 | |
| 4 | 2023 | 74 | |
| 5 | 2024 | 60 | |
| 6 | 2022 | 51 | |
| 7 | 2023 | 46 | |
| 8 | 2022 | 19 | |
| 9 | 2023 | 11 | |
| 10 | 2022 | 8 | |
| 11 | 2022 | 6 | |
| 12 | 2023 | 6 | |
| 13 | 2025 | 6 | |
| 14 | 2026 | 1 |
About Charles Zou
Charles Zou is a scholar working on Oncology, Hematology, Molecular Biology, Cell Biology and Infectious Diseases, having authored 14 papers that have together received 801 indexed citations. Recurring topics across this work include Protein Degradation and Inhibitors (8 papers), Ubiquitin and proteasome pathways (7 papers), Multiple Myeloma Research and Treatments (2 papers), CAR-T cell therapy research (2 papers), SARS-CoV-2 and COVID-19 Research (2 papers), Acute Myeloid Leukemia Research (1 paper), COVID-19 Clinical Research Studies (1 paper) and CRISPR and Genetic Engineering (1 paper). The work is most often cited by research in Oncology (229 citations), Molecular Biology (588 citations), Cancer Research (74 citations), Hematology (50 citations) and Immunology (78 citations). Charles Zou has collaborated with scholars based in United States, Switzerland and Germany. Frequent co-authors include Mikolaj Michal Slabicki, Eric S. Fischer, Benjamin L. Ebert, Katherine A. Donovan, Marko Cigler, Georg Petzold, Dakota J. Suchyta, Georg Kempf, Nicolas H. Thomä and Cristina Di Genua. Their work appears in journals such as Nature Chemical Biology, Nature, Molecular Cell, ACS Chemical Biology and Science.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.